PRESCRIBING · PART D · 2024
Total Rx claims
818
Beneficiaries
—
Total drug cost
$2.0M
Distinct drugs
18
Brand share
84.8%
Top prescribed drugs
Bictegrav/Emtricit/Tenofov Ala233 claims
Emtricitabine/Tenofov Alafenam137 claims
Raltegravir Potassium88 claims
Dolutegravir Sodium69 claims
Abacavir/Dolutegravir/Lamivudi43 claims
QUALITY · MIPS · 2024
Final MIPS score
88.0
Quality
82.8
Cost
77.2
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.55%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2025
No data available for this provider in 2025.
CROSS-REFERENCE